Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097460 · ClinicalTrials.gov registry record · Phase 1
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01097460 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT01097460, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
Interventions
- DRUG MM-111 + Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097460
The ClinicalTrials.gov registry entry for NCT01097460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MM-111 + Herceptin is the first listed.
NCT01097460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097460 about?
NCT01097460 is a clinical study titled "MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer". This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
What is the current status of trial NCT01097460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-04. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01097460?
The interventions under investigation include: MM-111 + Herceptin (DRUG).
Who is sponsoring clinical trial NCT01097460?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.